Table 2:

Associations of biomarkers advanced from discovery analysis with progressive fibrosing interstitial lung disease in the validation cohort

	OR (95% CI)	p value
AGER	0·51 (0·35–0·73)	0·0003
ANGPTL4	1·87 (1·20–2·98)	0·0064
BSG	0·96 (0·41–2·22)	0·92
CD276	1·39 (0·89–2·19)	0·16
CST7	1·18 (0·95–1·48)	0·15
CXCL10	0·98 (0·78–1·23)	0·88
CXCL17	1·68 (1·22–2·36)	0·0020
DPP10	1·70 (1·10–2·68)	0·018
FASLG	0·63 (0·41–0·97)	0·038
FCAR	1·63 (1·11–2·43)	0·014
FSTL3	1·49 (0·90–2·52)	0·13
HGF	2·09 (1·29–3·48)	0·0033
IL17C	1·70 (1·31–2·24)	<0·0001
IL1RN	1·18 (0·93–1·49)	0·18
ITGB6	3·04 (1·88–5·15)	<0·0001
KRT19	1·83 (1·39–2·48)	<0·0001
LIFR	1·49 (0·72–3·16)	0·29
MMP1	1·07 (0·84–1·36)	0·59
MMP10	1·65 (1·19–2·31)	0·0031
OSM	1.19 (0·96–1·48)	0·11
PLAUR	2·59 (1·42–4·89)	0·0025
PRSS8	2·52 (1·50–4·39)	0·0007
SCGB1A1	1·33 (0·94–1·91)	0·11
SCGB3A2	1·58 (1·25–2·04)	0·0002
SERPINB8	1·05 (0·87–1·28)	0·59
SPON1	2·14 (1·24–3·80)	0·0074
TFF2	1·24 (0·90–1·70)	0·19
TGFA	1·65 (1·14–2·42)	0·0089
TNFRSF11B	2·20 (1·31–3·79)	0·0034
TNFSF10	0·83 (0·43–1·57)	0·57
TNFSF11	0·86 (0·66–1·10)	0·24

ORs are per unit change in log2-transformed biomarker concentration. p values are based on univariable logistic regression. OR=odds ratio.